A new study suggests that an older GLP-1 drug may help protect the brains of people with early Alzheimers disease, supporting the case for further research on the class of medications originally developed for obesity and diabetes in neurological diseases
The medication already creates severe caloric restriction
Follow-up involves scheduling your next visit based on the protocol, tracking weight, measurements, and subjective energy over several weeks, and adjusting frequency or dose if side effects or a lack of benefit emerge
In either case, lifestyle modifications nutritional optimization, physical activity, and sleep remain integral to achieving and sustaining significant weight loss outcomes
Human biospecimens, clinical data and metabolite analysis of human samples Human biospecimens and deidentified clinical data were provided by the Wilmot Cancer Institute Biobank Shared Resource (BSR) at the University of Rochester